Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | Durvalumab |
Trade Name | Imfinzi |
Synonyms | MEDI4736 |
Drug Descriptions |
Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, and in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer (FDA.gov). |
DrugClasses | Immune Checkpoint Inhibitor 141 PD-L1/PD-1 antibody 83 |
CAS Registry Number | 1428935-60-7 |
NCIT ID | C103194 |